Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4904742 | 0.91 | MAPT (0.43) | TOP2AMAPTALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL4908310 | 0.83 | NR3C1 (0.42) | TOP2ASMN1; SMN2CNR1 | |
| SCHEMBL4901768 | 0.82 | DAO (0.46) | TOP2A | |
| SCHEMBL4907614 | 0.79 | TOP2A (0.42) | TOP2A | |
| SCHEMBL4910399 | 0.77 | CD274 (0.42) | ALDH1A1 | |
| SCHEMBL4904828 | 0.76 | DAO (0.41) | TOP2A | |
| SCHEMBL3264683 | 0.75 | CNR2 (0.49) | SMN1; SMN2CNR2CNR1 | |
| SCHEMBL4907263 | 0.75 | IKBKE (0.44) | TOP2AMAPTSMN1; SMN2 | |
| SCHEMBL4909671 | 0.74 | DAO (0.39) | TOP2A | |
| SCHEMBL4908508 | 0.74 | DAO (0.48) | TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269214-A1 | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | claimed |
| EP-1861393-A2 | PYRROLE DERIVATIVES AS DNA GYRASE AND TOPOISOMERASE INHIBITORS | AstraZeneca AB (SE) | 2007-12-05 | — | — | EP | claimed |
| WO-2006092599-A2 | PYRROLE DERIVATIVES AS DNA GYRASE AND TOPOISOMERASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-09-08 | — | — | WO | claimed |
| US-20080269214-A1 | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269214-A1 | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors | TOP1, TOP2A, TOP2B | TOP2A 2/4885MAPT 2515/4885ALDH1A1 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.